论文部分内容阅读
目的:探讨注射用血塞通(冻干粉)在23G微创玻切手术治疗糖尿病性玻璃体积血中的作用。方法:选取我院收治的2型糖尿病性玻璃体积血70例,将其随机分为两组,均给予常规血糖控制及23G微创玻切手术治疗,实验组于手术前给予注射用血塞通。对比两组患者的手术时间、术后并发症的发生率以及视力恢复情况。结果:实验组的平均手术时间明显短于对照组,术后出血、房性炎症、视网膜脱离、新生血管性青光眼并发症的发生率均明显低于对照组,差异有统计学意义(P<0.05);实验组视力恢复的总有效率显著高于与对照组,差异有统计学意义(P<0.05)。结论:术前应用注射用血塞通能够明显提高23G微创玻切手术治疗糖尿病性玻璃体积血的临床疗效,值得临床推广。
Objective: To investigate the role of Xuesaitong injection (lyophilized powder) in the treatment of diabetic vitreous hemorrhage by 23G minimally invasive vitrectomy. Methods: Seventy patients with type 2 diabetic vitreous hemorrhage admitted to our hospital were randomly divided into two groups. All patients were given conventional blood glucose control and 23G minimally invasive vitrectomy. The experimental group was given Xuese . The operation time, postoperative complications and visual acuity recovery were compared between the two groups. Results: The mean operation time of the experimental group was significantly shorter than that of the control group. The incidence of postoperative bleeding, atrial inflammation, retinal detachment and neovascular glaucoma were significantly lower than those of the control group (P <0.05 ); The total effective rate of visual acuity recovery in experimental group was significantly higher than that in control group, the difference was statistically significant (P <0.05). Conclusion: Preoperative application of Xuesaitong injection can significantly improve the clinical efficacy of 23G minimally invasive vitrectomy in the treatment of diabetic vitreous hemorrhage, which is worthy of clinical promotion.